FORM 5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROV	⁄AL
OMB Number:	3235-0362
Estimated average burden	
nours per response:	1.0

hours per response:

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Form 3 Holdir	ngs Reported.									
X Form 4 Trans	actions Reported.									
Name and Address of Reporting Person* Yanez Michelle		son [*]	2. Issuer Name and Ticker or Trading Symbol Inhibitor Therapeutics, Inc. [INTI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Yanez Mic	<u>nene</u>		,—————————————————————————————————————	X	Director	10% Owner				
					Officer (give title	Other (specify				
(Last)	(First)	(Middle)	3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year)		below)	below)				
C/O INHIBIT	OR THERAPUTION	CS, INC.,	12/31/2024							
900 WEST PI	LATT ST, SUITE 20	00								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	- 1	idual or Joint/Group Filing					
TAMPA	FL	33606		X	Form filed by One Rep	· ·				
					Form med by More than	n One Reporting Person				
(City)	(State)	(Zip)								

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	1. Title of Security (Instr. 3)	Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.	4. Securities Acquire (Instr. 3, 4 and 5)	ed (A) or D	,	Securities	Form: Direct	7. Nature of Indirect Beneficial Ownership (Instr. 4)
					Amount	(A) or (D)	Price			
	Common Stock	12/02/2024		G4	250,000	A	\$0	1,146,271	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	Securities Beneficially Owned Following	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				(A)	(D)	Date Exercisable	Expiration Date		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)		

Explanation of Responses:

/s/ Michelle Yanez

02/19/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).